Sunday, November 22, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Press releaseGlobeNewswire· April 13, 2026

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

View original at globenewswire.com
XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset • VB4-P5 – novel new chemical entity with potential to address significant unmet need in rare and large-market chronic kidney disease • CALGARY, Alberta, April 13, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc…
Opening lines of the source · GlobeNewswire · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The addressable market for kidney disease treatment is estimated to exceed 10 million individuals

    60% confidence
  • VB4-P5 has the potential to be a new treatment for mid-late stage chronic kidney disease, slow kidney disease progression and accompanying fibrosis

    60% confidence
  • VB4-P5 program is directly aligned with XORTX's strategic focus on developing innovative therapies to treat individuals with progressive kidney disease and broadens pipeline with a new technological direction

    60% confidence
  • No currently approved therapies specifically target or reverse kidney fibrosis

    60% confidence
  • Early preclinical data from the VB4-P5 program demonstrate the potential of this potent small molecule to inhibit and possibly reverse kidney fibrosis

    60% confidence

Cited in these Via News reports